These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 11858976)

  • 41. Aggregated adverse-events outcomes in oncology phase III reports: A systematic review.
    Maillet D; Gan HK; Blay JY; You B; Péron J
    Eur J Cancer; 2016 Jan; 52():26-32. PubMed ID: 26630531
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [The Urologic Cooperative Group of the EORTC. Structure, scope, research, results].
    Pavone-Macaluso M; Corselli G; Ingargiola GB; Serretta V
    Arch Ital Urol Androl; 1997 Sep; 69(4):209-15. PubMed ID: 9417293
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Quality assurance in surgical oncology (QASO) within the European Organization for Research and Treatment of Cancer (EORTC): current status and future prospects.
    Landheer ML; Therasse P; van de Velde CJ
    Eur J Cancer; 2001 Aug; 37(12):1450-62. PubMed ID: 11506950
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Multidisciplinary quality assurance and control in oncological trials: Perspectives from European Organisation for Research and Treatment of Cancer (EORTC).
    ;
    Eur J Cancer; 2017 Nov; 86():91-100. PubMed ID: 28964907
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cross-cultural development of a quality-of-life measure for patients with melanoma: phase 3 testing of an EORTC Melanoma Module.
    Winstanley JB; Young TE; Boyle FM; Bergenmar M; Bottomley A; Burmeister B; Campana LG; Garioch JJ; King M; Nikolic DV; van de Poll-Franse LV; Saw R; Thompson JF; White EG;
    Melanoma Res; 2015 Feb; 25(1):47-58. PubMed ID: 25325247
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The European Organisation for Research and Treatment of Cancer strategy for new drug development in brain tumors.
    Lacombe D; Brandes AA; van den Bent M
    Semin Oncol; 2003 Dec; 30(6 Suppl 19):77-80. PubMed ID: 14765392
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Achievements and goals of the EORTC Invasive Fungal Infections Group. European Organisation for Research and Treatment of Cancer.
    de Pauw BE; Herbrecht R; Meunier F;
    Eur J Cancer; 2002 Mar; 38 Suppl 4():S88-93. PubMed ID: 11858972
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Recruiting long-term survivors of European Organisation for Research and Treatment of Cancer phase III clinical trials into quality of life studies: challenges and opportunities.
    van Leeuwen M; Efficace F; Fosså SD; Bolla M; De Giorgi U; de Wit R; Holzner B; van de Poll-Franse LV; van Poppel H; White J; Collette L; Osanto S; Aaronson NK; ; ;
    Eur J Cancer; 2014 Jul; 50(11):1957-63. PubMed ID: 24820932
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Management of infection in cancer patients. studies of the EORTC International Antimicrobial Therapy Group (IATG).
    Viscoli C;
    Eur J Cancer; 2002 Mar; 38 Suppl 4():S82-7. PubMed ID: 11858971
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The European Organization for Research and Treatment of Cancer (EORTC) Malignant Melanoma Cooperative Group 25th anniversary.
    Melanoma Res; 1995 Feb; 5(1):3. PubMed ID: 7734954
    [No Abstract]   [Full Text] [Related]  

  • 51. Rubitecan: 9-NC, 9-Nitro-20(S)-camptothecin, 9-nitro-camptothecin, 9-nitrocamptothecin, RFS 2000, RFS2000.
    Drugs R D; 2004; 5(5):305-11. PubMed ID: 15357630
    [TBL] [Abstract][Full Text] [Related]  

  • 52. High conformality radiotherapy in Europe: thirty-one centres participating in the quality assurance programme of the EORTC prostate trial 22991.
    Ataman F; Poortmans P; Davis JB; Bernier J; Giraud JY; Kouloulias VE; Pierart M; Bolla M
    Eur J Cancer; 2004 Nov; 40(16):2411-6. PubMed ID: 15519513
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Melanoma Vaccine--AVAX Technologies: DNP-VACC, M-Vax.
    BioDrugs; 2003; 17(1):69-72. PubMed ID: 12534322
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Quality assurance of the EORTC 26981/22981; NCIC CE3 intergroup trial on radiotherapy with or without temozolomide for newly-diagnosed glioblastoma multiforme: the individual case review.
    Ataman F; Poortmans P; Stupp R; Fisher B; Mirimanoff RO
    Eur J Cancer; 2004 Jul; 40(11):1724-30. PubMed ID: 15251162
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The European Organization for Research and Treatment of Cancer (EORTC).
    Tubiana M
    Int J Radiat Oncol Biol Phys; 1988; 14 Suppl 1():S13-6. PubMed ID: 3391805
    [No Abstract]   [Full Text] [Related]  

  • 56. The role of interleukin-2 in the management of stage IV melanoma: the EORTC melanoma cooperative group program.
    Keilholz U; Eggermont AM
    Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S99-103. PubMed ID: 10685668
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Treatment influencing down-staging in EORTC Melanoma Group sentinel node histological protocol compared with complete step-sectioning: a national multicentre study.
    Riber-Hansen R; Hastrup N; Clemmensen O; Behrendt N; Klausen S; Ramsing M; Spaun E; Hamilton-Dutoit SJ; Steiniche T
    Eur J Cancer; 2012 Feb; 48(3):347-52. PubMed ID: 22023888
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Human tissue research: EORTC recommendations on its practical consequences.
    Teodorovic I; Therasse P; Spatz A; Isabelle M; Oosterhuis W
    Eur J Cancer; 2003 Nov; 39(16):2256-63. PubMed ID: 14556915
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Critical aspects to achieve a high-quality melanoma clinic.
    Dummer R; Ramelyte E; Levesque M; Goldinger SM; Braun RP
    Curr Opin Oncol; 2017 Mar; 29(2):145-150. PubMed ID: 28027104
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Sex is an independent prognostic indicator for survival and relapse/progression-free survival in metastasized stage III to IV melanoma: a pooled analysis of five European organisation for research and treatment of cancer randomized controlled trials.
    Joosse A; Collette S; Suciu S; Nijsten T; Patel PM; Keilholz U; Eggermont AM; Coebergh JW; de Vries E
    J Clin Oncol; 2013 Jun; 31(18):2337-46. PubMed ID: 23690423
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.